You are here

Our science / Clinical Trials / Find a Trial / NCT00252668

Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects

Back to Search Print Save as PDF Bookmark Trial

NCT00252668

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Rheumatoid Arthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subjects who completed the previous double-blind,randomized study.

- Ability to reconstitute and self-inject test etanercept (ETN) or have a designee who
can do so.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Dose of prednisone>10 mg/day (or equivalent) or dose changed within 2 weeks before
week 0 evaluation.

- Clinically relevant concurrent medical events including: uncompensated congestive
heart failure (CHF), diagnosis of multiple sclerosis or other central demyelinating
diseases, presence or history of confirmed blood dyscrasias, cancer or history of
cancer, serious infection within 1 month of test article administration or active
infection at week 0.

NCT00252668
Pfizer
Completed
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Rheumatoid Arthritis
Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate
NCT02996500
All Genders
18+
Years
Multiple Sites
Osteoarthritis
Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement
NCT02674386
All Genders
18+
Years
Multiple Sites
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
NCT03334851
All Genders
18+
Years
Multiple Sites
Hip Osteoarthritis, Knee Osteoarthritis
Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.
NCT02709486
All Genders
18+
Years
Multiple Sites
Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
An Open-Label, Multicentre, Extension Study of the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects
This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis. All subjects will receive combination treatment with etanercept and methotrexate.
Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: Etanercept
  • Drug: Methotrexate
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
300
September 2005
Not Provided

Inclusion Criteria:

  • Subjects who completed the previous double-blind,randomized study.
  • Ability to reconstitute and self-inject test etanercept (ETN) or have a designee who can do so.

Exclusion Criteria:

  • Dose of prednisone>10 mg/day (or equivalent) or dose changed within 2 weeks before week 0 evaluation.
  • Clinically relevant concurrent medical events including: uncompensated congestive heart failure (CHF), diagnosis of multiple sclerosis or other central demyelinating diseases, presence or history of confirmed blood dyscrasias, cancer or history of cancer, serious infection within 1 month of test article administration or active infection at week 0.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00252668
0881A1-101631
B1801221
0881A1-400
Not Provided
Not Provided
Not Provided
Not Provided
Wyeth is now a wholly owned subsidiary of Pfizer
Not Provided
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For Germany, [email protected]
Principal Investigator: Trial Manager For Sweden, Denmark and Norway, [email protected]
Principal Investigator: Trial Manager For Belgium, [email protected]
Principal Investigator: Trial Manager For Greece, [email protected]
Principal Investigator: Trial Manager For Czech Republic, [email protected]
Principal Investigator: Trial Manager For Romania, [email protected]
Principal Investigator: Trial Manager For Poland, [email protected]
Principal Investigator: Trial Manager For Spain, Italy, Portugal, the Netherlands, and Finland, [email protected]
Wyeth is now a wholly owned subsidiary of Pfizer
May 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now